Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: CNS partial response (PR) is achieved if all of the following are satisfied: secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression on non-measurable lesions secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new CNS lesions (defined as any new lesion >/= 6 mm in LD) secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Stable or decreasing steroid dose secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No new/progressive tumor-related neurologic signs or symptoms secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |